Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-10-04

Clinical Trial Update: Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 head-to-head trial comparing paliperidone palmitate with RISPERDAL CONSTA in adults with schizophrenia has completed, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INVEGA SUSTENNA (PALIPERIDONE PALMITATE)
  • Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2011-10-04